Staar surgical reports first quarter 2024 results

Lake forest, calif.--(business wire)--staar surgical company (nasdaq: k), a leading developer, manufacturer and marketer of the evo family of implantable collamer® lenses (evo icl™) for myopia, astigmatism and presbyopia, today reported financial results for the first quarter ended march 29, 2024. first quarter 2024 overview net sales up 5% to $77.4 million and up 7% in constant currency icl sales up 9% and units up 2% gross margin at 78.9% vs. 78.3% year ago net loss of $3.3 million or $0.07 l.
K Ratings Summary
K Quant Ranking